Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline
PMLive
|
April 1, 2021
X min read
PMLive
|
April 1, 2021
Share on Social
More like this
Media
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
Press
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
